Minal Barve, MD
Enriched profileChief Medical Officer and Executive Medical Director, Mary Crowley Cancer Research; Medical Oncologist, Texas Oncology · Mary Crowley Cancer Research
Minal Barve is Chief Medical Officer and Executive Medical Director, Mary Crowley Cancer Research; Medical Oncologist, Texas Oncology at Mary Crowley Cancer Research. OpenAlex indexes 418 publications with 7,682 citations (h-index 35); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Minal Barve, M.D., is Chief Medical Officer and Executive Medical Director, Mary Crowley Cancer Research. The public record shows 418 publications with 7,682 citations (h-index 35), centered on Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 27 companies.
- Most recent indexed publication: 2025 · Clinical cancer research
- Top research focus: Lung Cancer Treatments and Mutations
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 27 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 88.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- A Study of VET3-TGI in Patients With Solid Tumors
Sponsor: KaliVir Immunotherapeutics
- HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors
Sponsor: HighField Biopharmaceuticals Corporation
- Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Sponsor: Intezyne Technologies, Inc.
Industry payments
Updated 16 Oct 2026
27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- CATALYST PHARMACEUTICALS, INC.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
39.8%Parenteral Iron Replacement22.5%Iron sucrose100%Part B, office-administered≥26 patientsErythropoiesis-stimulating Agent17%Darbepoetin alfa100%Part B, office-administered≥25 patients+ 3 more classes in this area
Metabolism & gastrointestinal
30%Other antiemetics25.9%Fosaprepitant100%Part B, office-administered≥39 patientsSerotonin-3 Receptor Antagonist3.9%Palonosetron hcl58%Granisetron hydrochloride41%Ondansetron Hcl1%Ondansetron Odt1%Part D + Part B<11 patients+ 3 more classes in this area
Cancer & immunology
16.2%Microtubule Inhibitor13.4%Paclitaxel100%Part B, office-administered≥15 patientsNucleoside Metabolic Inhibitor1%Fluorouracil63%Gemcitabine hydrochloride37%Part B, office-administered≥15 patients+ 9 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
139 congress contributions (2007–2026) across AACR, ASCO, ASH, ESMO, SABCS per OpenAlex. The most recent:
- Abstract CT198: Phase 1 clinical trial of a first-in-class antagomir therapeutic against advanced solid tumors
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Clinical cancer research
Clinical Trial2025 - HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.
Journal of clinical oncology
Clinical Trial2025 - Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Cancer discovery
Clinical Trial2024 - A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01
- 02Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12CArticle520 citations2022
- 03Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyArticle467 citations2021
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/minal-barve-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →texasoncology.com ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Member
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗ - Member
Texas Medical Association
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
- Medical Director
Greater Dallas Arya Samaj (GDAS) Cancer Clinic
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →texasoncology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center